What does the FDA advise for starting HRT

DISCLOSURE: Voshell's Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

According to FDA.gov, starting HRT should follow the principle of using the lowest effective dose for the shortest duration needed to treat menopausal symptoms, with the treatment plan based on an individual's health history, risks, and goals.

Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

What the FDA Recommends When Beginning HRT

According to FDA.gov, the guiding framework for initiating HRT is straightforward: start at a low dose, align the plan with the patient's individual profile, and monitor regularly. This approach aims to maintain symptom relief while keeping risk as low as possible.

• Use the lowest effective dose: According to FDA-approved prescribing information, beginning with a small amount of estrogen — or estrogen plus progestogen if the patient has a uterus — may reduce exposure while still addressing symptoms.
• Use it for the shortest time needed: According to FDA.gov, there is no fixed duration limit, but ongoing use at higher doses requires clear evidence of continued benefit and acceptable risk for the individual patient, as assessed by a qualified prescriber.
• Match the treatment to symptoms: Hot flashes, night sweats, and vaginal dryness may respond differently to different forms of commercially available hormone therapy, such as pills, patches, or creams. A qualified prescriber may help determine the appropriate form.
• Have a risk assessment before starting: According to ACOG, a qualified prescriber should review cardiovascular, breast, clotting, liver, and bone health history before initiating hormone therapy.
• Reassess regularly: According to FDA.gov, clinicians should confirm at least annually that the dose remains appropriate and that benefits continue to outweigh risks.
• Use progestogen if the uterus is intact: According to FDA-approved prescribing information, progestogen is added to estrogen therapy to reduce the risk of endometrial hyperplasia and carcinoma in patients who have not had a hysterectomy.
• Consider non-oral forms when applicable: According to NAMS, transdermal forms such as patches, gels, and sprays may be associated with lower clotting risk compared to oral estrogen, as they bypass first-pass liver metabolism. A qualified prescriber may evaluate whether this distinction is relevant for a given patient.

Why the FDA Gives This Guidance

According to FDA Drug Safety Communication, estrogen-containing products carry boxed warnings related to stroke, deep vein thrombosis, and pulmonary embolism, among other risks. The FDA's lowest-effective-dose guidance is intended to help mitigate these risks while still allowing qualified prescribers to address symptoms that significantly affect quality of life.

According to FDA.gov, this framework does not impose a strict time limit on HRT use. Rather, it requires that continued use reflect an ongoing, individualized assessment by a qualified prescriber in which benefits remain greater than risks for that patient specifically.